ICON Public’s (ICLR) “Outperform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of ICON Public (NASDAQ:ICLR) in a research note issued to investors on Wednesday,Benzinga reports. Royal Bank of Canada currently has a $263.00 target price on the medical research company’s stock.

Other equities analysts have also recently issued reports about the company. Leerink Partnrs upgraded ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Citigroup lowered their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. reduced their price objective on shares of ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. William Blair reiterated an “outperform” rating on shares of ICON Public in a report on Tuesday. Finally, Barclays decreased their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Trading Down 0.4 %

NASDAQ:ICLR opened at $199.47 on Wednesday. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The business has a fifty day moving average of $210.30 and a 200-day moving average of $269.51. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. The stock has a market cap of $16.46 billion, a price-to-earnings ratio of 22.24, a PEG ratio of 1.59 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $3.10 EPS. Equities analysts predict that ICON Public will post 13.41 earnings per share for the current year.

Institutional Trading of ICON Public

Hedge funds have recently bought and sold shares of the stock. Steph & Co. lifted its stake in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after buying an additional 55 shares during the period. GAMMA Investing LLC raised its holdings in ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public in the 3rd quarter worth approximately $11,672,000. Icon Wealth Advisors LLC increased its position in shares of ICON Public by 861.1% during the third quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock valued at $3,797,000 after purchasing an additional 11,840 shares during the period. Finally, First Horizon Advisors Inc. raised its stake in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. 95.61% of the stock is owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.